<DOC>
	<DOCNO>NCT00699296</DOCNO>
	<brief_summary>This study ass safety , efficacy pharmacokinetics oral LBH589 Japanese adult patient refractory cutaneous T-Cell Lymphoma adult T-cell leukemia/lymphoma . LBH589 administer orally day three day per week .</brief_summary>
	<brief_title>Study Oral LBH589 Patients With Cutaneous T-cell Lymphoma Adult T-cell Leukemia/Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion : CTCL : Biopsyconfirmed MF SS stag IBIVA2 . Patients SS bone marrow involvement also eligible . Patients transform CTCL eligible . ATL : Patient cytologically histopathologically confirm lymphoma . Lymphoma identify tumor derive peripheral Tcells cell surface marker . ATL : Patients positivity antiHTLV1 antibody Patients must receive least two systemic therapy regimen . Patients must disease progression follow recent treatment regimen . Age ≥ 20 year ECOG Performance Status ≤ 2 Written inform consent obtain prior study specific screening procedure Exclusion criterion : Patients history primary CNS tumor Any history presence brain metastases Patients peripheral neuropathy ≥ CTCAE grade 2 Patients unresolved diarrhea &gt; CTCAE grade 1 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 Patients concurrent severe and/or uncontrolled liver renal disease Patients use sodium valproate ≤5 day prior start study drug Patients active bleeding diathesis treatment therapeutic dos sodium warfarin antivitamin K drug Patients receive investigational drug chemotherapy undergone major surgery ≤ 3 week prior start study drug recover side effect therapy Patients receive biologic therapy , target therapy ( e.g . denileukin diftitix ) , vaccine , systemic steroid immunotherapy ≤ 2 week prior start study treatment recover side effect therapy Patients receive wide field radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start study drug recover side effect therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>LBH589</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>cutaneous T-ceII lymphoma</keyword>
	<keyword>adult T-cell leukemia</keyword>
</DOC>